Varvara A. Orekhova
Research Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Varvara A. Orekhova.
International Journal of Molecular Sciences | 2016
Veronika A. Myasoedova; Kirichenko Tv; Alexandra A. Melnichenko; Varvara A. Orekhova; Alessio Ravani; Paolo Poggio; Igor A. Sobenin; Yuri V. Bobryshev; Alexander N. Orekhov
The risk of cardiovascular disease and atherosclerosis progression is significantly increased after menopause, probably due to the decrease of estrogen levels. The use of hormone replacement therapy (HRT) for prevention of cardiovascular disease in older postmenopausal failed to meet expectations. Phytoestrogens may induce some improvements in climacteric symptoms, but their effect on the progression of atherosclerosis remains unclear. The reduction of cholesterol accumulation at the cellular level should lead to inhibition of the atherosclerotic process in the arterial wall. The inhibition of intracellular lipid deposition with isoflavonoids was suggested as the effective way for the prevention of plaque formation in the arterial wall. The aim of this double-blind, placebo-controlled clinical study was to investigate the effect of an isoflavonoid-rich herbal preparation on atherosclerosis progression in postmenopausal women free of overt cardiovascular disease. One hundred fifty-seven healthy postmenopausal women (age 65 ± 6) were randomized to a 500 mg isoflavonoid-rich herbal preparation containing tannins from grape seeds, green tea leaves, hop cone powder, and garlic powder, or placebo. Conventional cardiovascular risk factors and intima-media thickness of common carotid arteries (cIMT) were evaluated at the baseline and after 12 months of treatment. After 12-months follow-up, total cholesterol decreased by 6.3% in isoflavonoid-rich herbal preparation recipients (p = 0.011) and by 5.2% in placebo recipients (p = 0.020); low density lipoprotein (LDL) cholesterol decreased by 7.6% in isoflavonoid-rich herbal preparation recipients (p = 0.040) and by 5.2% in placebo recipients (non-significant, NS); high density lipoprotein (HDL) cholesterol decreased by 3.4% in isoflavonoid-rich herbal preparation recipients (NS) and by 4.5% in placebo recipients (p = 0.038); triglycerides decreased by 6.0% in isoflavonoid-rich herbal preparation recipients (NS) and by 7.1% in placebo recipients (NS). The differences between lipid changes in the isoflavonoid-rich herbal preparation and placebo recipients did not reach statistical significance (p > 0.05). Nevertheless, the mean cIMT progression was significantly lower in isoflavonoid-rich herbal preparation recipients as compared to the placebo group (6 μm, or <1%, versus 100 μm, or 13%; p < 0.001 for the difference). The growth of existing atherosclerotic plaques in isoflavonoid-rich herbal preparation recipients was inhibited by 1.5-fold (27% versus 41% in the placebo group). The obtained results demonstrate that the use of isoflavonoid-rich herbal preparation in postmenopausal women may suppress the formation of new atherosclerotic lesions and reduce the progression of existing ones, thus promising new drug for anti-atherosclerotic therapy. Nevertheless, further studies are required to confirm these findings.
Vessel Plus | 2017
Margarita A. Sazonova; Anastasia I. Ryzhkova; Vasily V. Sinyov; Elena V. Galitsyna; Varvara A. Orekhova; Alexandra A. Melnichenko; Alexander N. Orekhov; Alessio Ravani; I. Sobenin
1Laboratory of Medical Genetics, Russian Cardiology Research and Production Complex, 121552 Moscow, Russia. 2Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia. 3Institute for Atherosclerosis Research, Skolkovo Innovative Centre, 121609 Moscow, Russia. 4Unit for the Study of Morphology and Arterial Function, Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.
Data in Brief | 2018
Tatiana V. Kirichenko; I. Sobenin; Zukhra B. Khasanova; Varvara A. Orekhova; Alexandra A. Melnichenko; Natalya A. Demakova; Andrey V. Grechko; Alexander N. Orekhov; Jorge L. Ble Castillo; Tatiana P. Shkurat
Despite the fact that the role of mitochondrial genome mutations in a number of human diseases is widely studied, the effect of mitochondrial heteroplasmy in the development of cardiovascular disease has not been adequately investigated. In this study, we compared the heteroplasmy levels of mtDNA from leukocytes for m.3256C>T, m.3336T>C, m.12315G>A, m.5178C>A, m.13513G>A, m.14459G>A, m.14846G>A, m.15059G>A, m.652insG and m.1555A>G mutations in CVD-free subjects and CVD patients in samples derived from Russian and Mexican populations. It was demonstrated that heteroplasmy level of m.5178C>A was associated with CVD in Russian men, and m.14459G>A – in Russian women. Mitochondrial heteroplasmy level of m.13513G>A and m.652insG were associated with CVD in Mexican men, and only m.652insG– in Mexican women. The levels of heteroplasmy for mitochondrial mutations m.3336T>C, m.5178C>A, m.14459G>A, m.14846G>A and m.1555A>G were significantly higher in CVD-free Mexican men, and for m.3256C>T, m.3336T>C, and m.14459G>A – in CVD-free Mexican women.
Vessel Plus | 2017
I. Sobenin; Varvara A. Orekhova; Andrey V. Grechko; Alexander N. Orekhov
1Department of Cardiovascular Pathology, National Medical Research Center of Cardiology, 121552 Moscow, Russia. 2Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia. 3Federal Scientific Clinical Center for Resuscitation and Rehabilitation, 109240 Moscow, Russia. 4Institute for Atherosclerosis Research, Skolkovo Innovative Center, 121609 Moscow, Russia.
International Journal of Cardiology | 2013
Igor A. Sobenin; Varvara A. Orekhova; A. Melnichenko; Yuri V. Bobryshev; Alexander N. Orekhov
Patologicheskaia fiziologiia i èksperimental'naia terapiia | 2013
Aladinsky Va; Nikita G. Nikiforov; Varvara A. Orekhova; Alexandra A. Melnichenko; Karagodin Vp; Igor A. Sobenin; Alexander N. Orekhov
Patologicheskaia fiziologiia i èksperimental'naia terapiia | 2012
Miasoedova Va; Kirichenko Tv; Varvara A. Orekhova; Igor A. Sobenin; Mukhamedova Nm; Martirosian Dm; Karagodin Vp; Alexander N. Orekhov
Atherosclerosis Supplements | 2008
Denis V. Aksenov; Varvara A. Orekhova; R.A. Kireev; I. V. Andrianova; A. N. Smirnov; Igor A. Sobenin; O. M. Panasenko
Patologicheskaia fiziologiia i èksperimental'naia terapiia | 2012
Alexander N. Orekhov; Igor A. Sobenin; Varvara A. Orekhova; Alexandra A. Melnichenko; Miasoedova Va; Mukhamedova Nm; Martirosian Dm; Pshezhetskiĭ Av; Karagodin Vp
Atherosclerosis Supplements | 2018
Igor A. Sobenin; Vasily V. Sinyov; Nikita G. Nikiforov; Zukhra B. Khasanova; Elena B. Romanenko; Varvara A. Orekhova; Tatiana V. Kirichenko; Alexander N. Orekhov